Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Radnor, Pennsylvania--(Newsfile Corp. - November 27, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's materially misleading statements, Novavax investors have suffered significant losses.

INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Alerts Novavax, Inc. (NVAX) Shareholders of Securities Fraud Class Action Lawsuit on Their Behalf

SAN DIEGO--(BUSINESS WIRE)-- #NVAXstock--The suit alleges defendants issued false statements concerning Novavax business and prospects, resulting in its stock trading at inflated prices.

NVAX ALERT: Investors with Substantial Losses Have Opportunity to Lead the Novavax, Inc. Class Action Lawsuit

RADNOR, Pa., Nov. 26, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX).

Important Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. Investors of Deadline in Securities Fraud Class Action Lawsuit and Encourages Investors with Significant Losses to Contact the Firm

The stock price of Novavax (NASDAQ: NVAX) has seen a solid 18% rise in just five trading sessions, while it is up a large 48% in a month (twenty-one trading days). The recent rise can be attributed to Novavax receiving an emergency use authorization for its Covid-19 vaccine shot in the Philippines.

What's Next For Novavax Stock After A Large 48% Rise In A Month?

Longeveron

Merck

Teladoc

Could rising coronavirus cases globally see these health care stocks be put back into the limelight?

4 Hot Health Care Stocks To Watch Right Now

Novavax is making good progress with SII backed regulatory filings.

Novavax: Some Burning Questions

Some good news on the regulatory front wasn't enough to make investors happy.

Why Novavax Was Wilting on Wednesday

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Novavax, Inc. (NASDAQ: NVAX) between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”), of the important January 11, 2022 lead plaintiff deadline. SO WHAT: If you purchased Novavax securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT:

EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Novavax, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – NVAX

San Francisco, California--(Newsfile Corp. - November 24, 2021) - Hagens Berman urges Novavax, Inc. (NASDAQ: NVAX) investors with significant losses to submit your losses now. Class Period: Mar. 2, 2021 - Oct. 19, 2021Lead Plaintiff Deadline: Jan. 11, 2022Visit: www.hbsslaw.com/investor-fraud/NVAX Contact An Attorney Now: NVAX@hbsslaw.com 844-916-0895Novavax, Inc. (NVAX) Securities Fraud Class Action: The lawsuit alleges that Defendants misrepresented Novavax's progress toward successfully developing its COVID-19 vacc

NVAX INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Notifies Novavax (NVAX) Investors of Lead Plaintiff Opportunity in Securities Fraud Class Action

GAITHERSBURG, Md., Nov. 24, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its submission to the Singapore Health Sciences Authority (HSA) for interim authorization of its COVID-19 vaccine under the Pandemic Special Access Route (PSAR).

Novavax Files for Interim Authorization of COVID-19 Vaccine in Singapore

Ocugen, Inc.

Will either of these hopeful vaccine makers continue to thrash the market?

Better Buy: Ocugen or Novavax?

San Diego, California--(Newsfile Corp. - November 23, 2021) - Robbins Geller Rudman & Dowd LLP announces that purchasers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, both dates inclusive (the "Class Period") have until January 11, 2022 to seek appointment as lead plaintiff in Sinnathurai v. Novavax, Inc., No. 21-cv-02910. Filed on November 12, 2021 in the District of Maryland, the Novavax class action lawsuit charges Novavax and...

NVAX DEADLINE: Novavax, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

GAITHERSBURG, Md., Nov. 23, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced that it will participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference.

Novavax to Participate in Evercore ISI's 4th Annual HealthCONx Virtual Conference

Boston, Massachusetts--(Newsfile Corp. - November 22, 2021) - The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ: NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm's investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email investors@tenlaw.com or call...

NVAX Investor Alert: Shareholder Lawsuit Filed

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming January 11, 2022 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). If you suffered a loss on your Novavax investments or would like to inquire about potentially pursuing clai

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Novavax, Inc. (NVAX)

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Novavax, Inc. ("Novavax” or the "Company") (NASDAQ: NVAX) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Novavax between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/nvax. This class

NVAX Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Novavax, Inc. Shareholders of Class Action and Lead Deadline: January 11, 2022

Radnor, Pennsylvania--(Newsfile Corp. - November 21, 2021) - The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX). The action charges Novavax with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of Novavax's materially misleading statements, Novavax investors have suffered significant losses.

Important January 11, 2022 Deadline Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Novavax, Inc. Investors of Securities Fraud Class Action Lawsuit

Moderna

Novavax has filed requests for the authorization of its coronavirus vaccine candidate in several countries.

Will Novavax Be Worth as Much as Moderna by 2025?

SAN DIEGO, Nov. 20, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Novavax, Inc. (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the "Class Period") have until January 11, 2022 to seek appointment as lead plaintiff in Sinnathurai v. Novavax, Inc., No.

NVAX ALERT: Novavax, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

CrowdStrike

Buying companies on the leading edge of innovation during a crash or steep correction can make you a lot richer over the long run.

3 Cutting-Edge Stocks to Buy If There's a Stock Market Crash

RADNOR, Pa., Nov. 19, 2021 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that a securities class action lawsuit has been filed against Novavax, Inc. ("Novavax") (NASDAQ: NVAX).

Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against Novavax, Inc. - NVAX

Live Nation

Pfizer

Here are three COVID-19 stock ideas: a vaccine biotech, a big pharma stock, and an investment in a reopening.

What Are the Top COVID Plays for 2022?

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 11, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Novavax, Inc. (“Novavax” or the “Company”) (NASDAQ: NVAX) securities between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). Investors suffering losses on their Novavax investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal righ

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Novavax, Inc. (NVAX)

Novavax stock (NASDAQ: NVAX) rose by about 12% over the last week (five trading days), outperforming the S&P 500 which was up around 1% over the same period. The stock also remains down by about 15% over the last month (21 trading days).

Will Novavax Stock Rise Further With E.U. Decision In The Offing?

RADNOR, Pa.--(BUSINESS WIRE)---- $NVAX--Kessler Topaz Meltzer & Check, LLP Reminds Novavax Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf

News for Novavax Stock (NVAX)